Amlodipine Reduces Cardiac Iron Overload In Patients With Thalassemia Major: A Pilot Trial.

dc.creatorFernandes, Juliano Lara
dc.creatorSampaio, Erika Fontana
dc.creatorFertrin, Kleber
dc.creatorCoelho, Otavio Rizzi
dc.creatorLoggetto, Sandra
dc.creatorPiga, Antonio
dc.creatorVerissimo, Monica
dc.creatorSaad, Sara T
dc.date2013-Sep
dc.date2015-11-27T13:31:54Z
dc.date2015-11-27T13:31:54Z
dc.date.accessioned2018-03-29T01:18:05Z
dc.date.available2018-03-29T01:18:05Z
dc.identifierThe American Journal Of Medicine. v. 126, n. 9, p. 834-7, 2013-Sep.
dc.identifier1555-7162
dc.identifier10.1016/j.amjmed.2013.05.002
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/23830536
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/200713
dc.identifier23830536
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1300946
dc.descriptionIron chelation therapy in patients with thalassemia major may not prevent iron overload in all organs, especially those in which iron enters cells through specific calcium channels. We designed a controlled pilot study to assess the potential of the calcium channel blocker amlodipine in strengthening the efficacy of iron chelation. Fifteen patients with thalassemia major undergoing chelation therapy were randomized to receive amlodipine added to standard treatment in a 1:2 allocation for 12 months. T2* values for assessment of iron overload in the liver and heart using magnetic resonance imaging were obtained at baseline and at 6 and 12 months. In the amlodipine-treated group, heart T2* increased significantly in comparison to baseline at 6 and 12 months (21.7 ± 7.2 ms to 28.2 ± 7.9 ms and 28.3 ± 8.0 ms, with P = .007 and .03, respectively), while no differences were observed in the control group (25.1 ± 8.8 ms to 24.7 ± 7.8 ms and 26.2 ± 11.4 ms; P = .99 and 0.95, respectively); significant differences between groups were observed at 6 months (28.2 ± 7.9 ms vs 24.7 ± 7.8 ms in the control group, P = .03). A significant reduction in ferritin levels also was observed in the treated group at 12 months. The use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart.
dc.description126
dc.description834-7
dc.languageeng
dc.relationThe American Journal Of Medicine
dc.relationAm. J. Med.
dc.rightsfechado
dc.rightsCopyright © 2013 Elsevier Inc. All rights reserved.
dc.sourcePubMed
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAmlodipine
dc.subjectAnalysis Of Variance
dc.subjectCalcium Channel Blockers
dc.subjectChelation Therapy
dc.subjectChi-square Distribution
dc.subjectFemale
dc.subjectHumans
dc.subjectIron Overload
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectMyocardium
dc.subjectPilot Projects
dc.subjectTreatment Outcome
dc.subjectBeta-thalassemia
dc.subjectIron Overload
dc.subjectMagnetic Resonance Imaging
dc.subjectThalassemia
dc.titleAmlodipine Reduces Cardiac Iron Overload In Patients With Thalassemia Major: A Pilot Trial.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución